On September 14, 2018 the FDA approved AJOVY (fremanezumab-vfrm) injection for the preventative treatment of migraines in adults. The medication is an injectable calcitonin-gene-related peptide (CGRP) antagonist. This is the second anti-CGRP treatment that has recently been approved. This treatment is available in both quarterly and monthly injections. AJOVY can be self-administered or administered in … Read more

Seattle Clinical Research Center is pleased to announce that the FDA has approved a new treatment for axillary hyperhidrosis, also known as excessive underarm sweating. This is a chronic skin condition that affects approximately 10 million people in the United States and causes people to sweat more than what is necessary for normal thermal regulation. … Read more

Seattle Clinical Research Center is excited to announce that the FDA has approved Aimovig, a new treatment developed specifically for migraine headache prevention. Migraine is a debilitating condition that impacts 38 million patients in the United States. Seattle Clinical Research Center conducted one of the pivotal clinical trials involved in the approval process. Aimovig is … Read more

Intrarosa (prasterone) was recently FDA approved to treat moderate to severe painful sexual intercourse (dyspareunia) caused by vulvar and vaginal atrophy (VVA). VVA is a common condition affecting up to 50% of postmenopausal women that results from the loss of estrogen during menopause. This causes the walls of the vagina and surrounding tissues to become … Read more